Leuko
Paul Hartung is an experienced executive in the life sciences and healthcare industries, currently serving as an independent board member at Leuko. Paul has previously served as Vice President of Corporate Development at Neutron Therapeutics, Inc., a Business Advisor at Confer Health, Inc., and Strategic Advisor at MassBio. Paul also founded, was president and CEO of Sonivance, and has served on the boards of SemiNex Corporation and Medical Development Group of Boston.
Paul Hartung studied mechanical engineering at the Massachusetts Institute of Technology, where they earned their BS and MS.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Leuko
Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is the first-line indicator for various medically relevant situations, ranging from chemotherapy management to the detection of life-threatening infections worldwide.